EPISODE · Jun 11, 2021 · 25 MIN
The Question of Investment in Antimicrobials
from Back Bay Life Science Report · host Back Bay Life Science Advisors
In this episode Jonathan Gertler, Back Bay’s CEO and Managing Partner, sits down with Dr. Peter Bak, Managing Director at Back Bay, to discuss Dr. Bak’s latest article in STAT News and to talk about the world of anti-infectives.Dr. Bak has more than ten years of expertise in infection and treatment. He began his research at Dartmouth Medical School and later continued at MIT, where he was an American Cancer Society Postdoctoral Fellow at the Koch Institute of Integrative Cancer Research.Topics include:-The landscape of antiinfectives, antimicrobials & antifungals -How commercial dynamics drive clinical unmet need -The role the pandemic played on development & investments -The deployment of cell therapies for viral diseases -Foundation support for anti-infectives -“Push incentives” to usher therapies into commercial stagesLink to Dr. Peter Bak's published article in STAT News, “Investment in antimicrobials was up in 2020, but much work remains," https://www.statnews.com/2021/04/28/investment-antimicrobials-uptick-2020-much-work-remains/
What this episode covers
In this episode Jonathan Gertler, Back Bay’s CEO and Managing Partner, sits down with Dr. Peter Bak, Managing Director at Back Bay, to discuss Dr. Bak’s latest article in STAT News and to talk about the world of anti-infectives.
NOW PLAYING
The Question of Investment in Antimicrobials
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Mar 3, 2026 ·44m
Feb 21, 2026 ·30m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m